Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 adalimumab versus placebo study in moderate to severe hidradenitis suppurativa
NL-OMON40003Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in hidradenitis suppurativa (HS) (5 arms), sponsored by AbbVie Inc. Primary endpoint: Primary efficacy endpoint. Started Oct 2012; status: active, not recruiting.
02
Drugs
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON40003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40003.